Dr. Drakeman has served as Genmab’s President and CEO since inception and is also a member of the board of directors. Dr. Drakeman has over eighteen years of experience working in the biotechnology industry, including establishing corporate partnerships with major pharmaceutical companies, managing clinical trials of monoclonal antibody-based products and developing government programs for financing biotechnology research. She previously served as a member of the faculty and administration at Princeton University and as Senior Vice President, Head of Business Development for Medarex, Inc. Dr. Drakeman serves on the board of BioNJ. She received a B.A. degree, from Mount Holyoke College, M.A., from Rutgers University, and M.A. and Ph.D., from Princeton University.

Prof. van de Winkel has served as our CSO since inception. Previously he was Vice President and Scientific Director of Medarex Europe. He is the author of over 270 scientific publications and has been responsible for a number of patents and pending patent applications. Prof. van de Winkel is one of the leading scientists in the study of antibodies and their interaction with the immune system. Prof. van de Winkel is a part-time Professor of Immunology at Utrecht University and also a member of the scientific advisory boards for BTF and Thuja Capital Healthcare Fund. He holds M.S. and Ph.D. degrees from the University of Nijmegen.

Dr. Møller has served as our COO since our inception. He has extensive experience in the biotechnology industry and in overseeing product development, manufacturing, clinical trials activities and human resources. Previous posts include Executive Vice President and Chief Medical and Operating Officer of Oxigene, Inc., President of IPC-Nordic A/S, and Medical Director for Synthélabo Scandinavia A/S. Dr. Møller is Chairman of the board at IPC-International, Plc and its 3 wholly owned subsidaries. He received his M.D. and Ph.D. degrees from the University of Copenhagen.

Mr. Eatwell joined Genmab in 2008 with extensive experience and a proven track record in leading international life science businesses, having spent 15 years working in Europe and 10 years in the US. Most recently, Mr. Eatwell served as Chief Financial Officer of Catalent Pharma Solutions, Inc., a USD 1.8 billion leading provider of manufacturing and packaging services for the pharmaceutical and biotech industry, with 33 facilities in 12 countries and 10,000 employees. Prior to Catalent Mr. Eatwell served as a divisional CFO of Cardinal Health, Inc., a fortune 20 global manufacturer and distributor of healthcare products and services, where he spearheaded the USD 3.3 billion sale of the Pharmaceutical Technologies and Services division to The Blackstone Group and was instrumental in creating the framework and building the infrastructure to support the newly created company, Catalent Pharma Solutions, Inc. Mr. Eatwell is a Chartered Accountant.

Dr. Lyles joined Genmab in 2005.  She has been engaged in biology-related businesses for nearly two decades, including a prior business development post with Medarex, Inc. She speaks frequently at licensing-related conferences and has served on professional committees for organizations including BIO, BioNJ, and the New Jersey Economic Development Authority.  Dr. Lyles earned undergraduate and graduate biology degrees from Yale and Princeton Universities.

Ms. Svedberg joined Genmab in 1999. She has extensive experience in international clinical drug development, both from large and small pharmaceutical industries. Previous posts include Head of Clinical Development (Europe) at Oxigene Europe AB and Senior Clinical Research Manager at Pharmacia & Upjohn AB (currently Pfizer). Ms. Svedberg earned E*MBA, M.Sc. (Radiation Physics) and medical bachelor degrees from Lund University.

Dr. Lund-Hansen joined Genmab as Vice President, Manufacturing in 2002. In 2008, he was appointed Senior Vice President, Technical Operations, responsible for Genmab’s manufacturing team and the development of the company’s manufacturing facilities.  Before joining Genmab, he was Director of Process Development and Manufacturing at Maxygen and previously held positions in Research and Development, Healthcare Business, Pharmaceutical Strategy Unit and the Biopharmaceutical Division at Novo Nordisk. While at Novo Nordisk, he was in charge of the global development of NovoSeven and was responsible for establishing the first NovoSeven manufacturing facility as well as the manufacture of tinzaparin and glucagon. He is an author of almost 30 publications and an examiner in Biochemistry for the University of Copenhagen.  Dr. Lund-Hansen holds an M.Sc in Biochemistry and gained his Ph.D. in human genetics in 1985.

Dr. Parren joined Genmab in 2002 and was appointed Senior Vice President in 2008. Previously he was an Associate Professor in the Department of Immunology at The Scripps Research Institute in La Jolla, California. He is author of 100+ scientific publications in the antibody field and is named inventor on over 20 patents and patent applications. He holds M.S. and Ph.D. degrees from the University of Amsterdam.

Dr. Baadsgaard has been a member of Genmab's Scientific Advisory Board since our inception. He joined Genmab as Medical Director in 2000 and in 2008 he was appointed Senior Vice President, Medical Affairs. Dr. Baadsgaard is a Board Certified Specialist in dermatology and has extensive clinical and scientific experience from both Denmark and the US. He is author of 100+ scientific peer-reviewed publications within clinical research and is named inventor on over 15 patents and patent applications. He received his M.D. degree from the University of Aarhus and his Dr.MSci. degree from the University of Copenhagen.